R&D Q3 Clinical trials round-up: July to September 2025 As the third quarter of 2025 draws to a close, the clinical research landscape has been marked by a surge of promising data and regulatory milestones.
News COVID-19 bites into Pfizer’s Q3, but biopharma revenues rise Pfizer is one of the front-runners in the race to approve a COVID-19 vaccine
News COVID-19 ventilator demand fuels Philips Q3 sales Huge demand for ventilators and patient monitors spurred third quarter sales for Royal Philips, the company announced.
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.